Continental perspectives on managing axial spondyloarthritis and psoriatic arthritis: approaches and insights from Latin America

Purpose of review This review provides a critical analysis of the management of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) in Latin America, emphasizing regional challenges, genetic diversity, healthcare disparities, and efforts to optimize patient care in resource-limited settings. Recent findings Recent literature highlights significant differences in treatment accessibility, healthcare infrastructure, and disease burden across Latin America considering the management of axSpA and PsA. Pan American league of associations for rheumatology (PANLAR) has established region-specific treatment recommendations adapted to the region that address these disparities while complementing international guidelines from assessment of spondyloarthritis international society – European alliance of associations for rheumatology (ASAS-EULAR) and group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). Limited access to biologics, high rates of diagnostic delay, and unique genetic and environmental factors shape disease management in this region. From the clinical perspective, the higher frequency of peripheral manifestations and the low frequency of HLA-B27 are remarkable. Summary Latin America faces distinct obstacles in axSpA and PsA management, requiring tailored strategies that integrate regional epidemiological characteristics, healthcare system disparities, and economic constraints. Supporting collaborative research networks across all countries and increasing access to advanced therapies are critical to enhance patient outcomes in SpA and PsA. Implementation of management strategies in the continent are required.